A survey of polivizumab for infants with cystic fibrosis in the UK [2]

Archives of Disease in Childhood

Volumn 92, Issue 1, 2007, Pages 87-88

  McCormick, J ^a   Southern, K W ^b  

^a ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; PALIVIZUMAB; ANTIVIRUS AGENT;

CHILDHOOD MORTALITY; COST BENEFIT ANALYSIS; CYSTIC FIBROSIS; DISEASE COURSE; DRUG EFFICACY; EVIDENCE BASED MEDICINE; FUNDING; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH SURVEY; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LETTER; LONG TERM CARE; MEDICAL RECORD; PATIENT IDENTIFICATION; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; QUESTIONNAIRE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RISK FACTOR; TREATMENT INDICATION; TREATMENT OUTCOME; UNITED KINGDOM; COHORT ANALYSIS; EPIDEMIOLOGY; INFANT; MORTALITY; NEWBORN; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; COHORT STUDIES; CYSTIC FIBROSIS; GREAT BRITAIN; HEALTH CARE SURVEYS; HUMANS; INFANT; INFANT, NEWBORN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS;

EID: 33846386104     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2006.0105338     Document Type: Letter

References (2)

1. The IMpact RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalisation from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7.
2. Malfroot A, Adam G, Ciofu O, et al. Immunisation in the current management of cystic fibrosis patients. J Cyst Fibros 2005;4:77-87.